» Articles » PMID: 35204404

Deep Learning Prediction of Response to Anti-VEGF Among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS)

Overview
Specialty Radiology
Date 2022 Feb 25
PMID 35204404
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic macular edema (DME) is the most common cause of visual impairment among patients with diabetes mellitus. Anti-vascular endothelial growth factors (Anti-VEGFs) are considered the first line in its management. The aim of this research has been to develop a deep learning (DL) model for predicting response to intravitreal anti-VEGF injections among DME patients. The research included treatment naive DME patients who were treated with anti-VEGF. Patient's pre-treatment and post-treatment clinical and macular optical coherence tomography (OCT) were assessed by retina specialists, who annotated pre-treatment images for five prognostic features. Patients were also classified based on their response to treatment in their post-treatment OCT into either good responder, defined as a reduction of thickness by >25% or 50 µm by 3 months, or poor responder. A novel modified U-net DL model for image segmentation, and another DL EfficientNet-B3 model for response classification were developed and implemented for predicting response to anti-VEGF injections among patients with DME. Finally, the classification DL model was compared with different levels of ophthalmology residents and specialists regarding response classification accuracy. The segmentation deep learning model resulted in segmentation accuracy of 95.9%, with a specificity of 98.9%, and a sensitivity of 87.9%. The classification accuracy of classifying patients' images into good and poor responders reached 75%. Upon comparing the model's performance with practicing ophthalmology residents, ophthalmologists and retina specialists, the model's accuracy is comparable to ophthalmologist's accuracy. The developed DL models can segment and predict response to anti-VEGF treatment among DME patients with comparable accuracy to general ophthalmologists. Further training on a larger dataset is nonetheless needed to yield more accurate response predictions.

Citing Articles

Differences in Artificial Intelligence-Based Macular Fluid Parameters Between Clinical Stages of Diabetic Macular Edema and Their Relationship with Visual Acuity.

Mitamura M, Saito M, Hirooka K, Dong Z, Ando R, Kase S J Clin Med. 2025; 14(3).

PMID: 39941675 PMC: 11818321. DOI: 10.3390/jcm14031007.


Application of deep learning algorithm for judicious use of anti-VEGF in diabetic macular edema.

Mondal A, Nandi A, Pramanik S, Mondal L Sci Rep. 2025; 15(1):4569.

PMID: 39915516 PMC: 11802850. DOI: 10.1038/s41598-025-87290-3.


Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema.

Leng X, Shi R, Xu Z, Zhang H, Xu W, Zhu K Sci Rep. 2024; 14(1):30270.

PMID: 39632987 PMC: 11618618. DOI: 10.1038/s41598-024-82007-4.


Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema.

Yao J, Lim J, Lim G, Ong J, Ke Y, Tan T Eye Vis (Lond). 2024; 11(1):23.

PMID: 38880890 PMC: 11181581. DOI: 10.1186/s40662-024-00389-y.


Artificial Intelligence and Glaucoma: Going Back to Basics.

AlRyalat S, Singh P, Kalpathy-Cramer J, Kahook M Clin Ophthalmol. 2023; 17:1525-1530.

PMID: 37284059 PMC: 10239633. DOI: 10.2147/OPTH.S410905.


References
1.
Ashraf M, Souka A, Adelman R . Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol. 2016; 100(12):1596-1604. DOI: 10.1136/bjophthalmol-2016-308388. View

2.
Martin D, Maguire M, Fine S, Ying G, Jaffe G, Grunwald J . Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388-98. PMC: 3389193. DOI: 10.1016/j.ophtha.2012.03.053. View

3.
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T . Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676-82. PMC: 3855844. DOI: 10.1038/nmeth.2019. View

4.
Lalwani G, Rosenfeld P, Fung A, Dubovy S, Michels S, Feuer W . A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1):43-58.e1. DOI: 10.1016/j.ajo.2009.01.024. View

5.
Shah A, Yonekawa Y, Todorich B, Van Laere L, Hussain R, Woodward M . Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection. J Vitreoretin Dis. 2017; 1(3):169-174. PMC: 5668872. DOI: 10.1177/2474126416682569. View